Related Experiment Videos
Improved prospects for cancer therapy with radiolabeled antibody fragments and peptides?
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology·2021
Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2021
Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2020
Promising clinical performance of pretargeted immuno-PET with anti-CEA bispecific antibody and gallium-68-labelled IMP-288 peptide for imaging colorectal cancer metastases: a pilot study.
European journal of nuclear medicine and molecular imaging·2020
Immunization with HIV-1 envelope T20-encoding DNA vaccines elicits cross-clade neutralizing antibody responses.
Human vaccines & immunotherapeutics·2017
Anti-CEA antibody fragments labeled with [(18)F]AlF for PET imaging of CEA-expressing tumors.
Bioconjugate chemistry·2014
From Metabolism to Molecular Phenotype: Carbonic Anhydrase IX-Targeted [68Ga]Ga-DPI-4452 PET/CT in Renal Cell Carcinoma: A Prospective Multicenter Comparison with [18F]FDG PET/CT.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
From Bench to Bedside: A Critical Appraisal of Somatostatin Receptor Antagonists in the Theranostic Management of Neuroendocrine Neoplasms.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Beta Atlas: Charting Global Production of Nonconventional β--Emitters for Targeted Radiopharmaceutical Therapy-Part 1.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Are Urooncologists Onboard?
Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Radiopharmaceutical Therapy-Linked Tumor Resistance: Immune Evasion, Nonimmune Mechanisms, and Immunometabolic Vulnerabilities.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Dosimetry-Driven Personalization of Radiopharmaceutical Therapies: Evidence and Opportunities.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026